Cite
Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes.
MLA
Gras, Emmanuelle, et al. “Extended Remdesivir Administration in Haematological Patients with Malignancies and COVID-19 during the Omicron Era: Safety and Outcomes.” Journal of Antimicrobial Chemotherapy (JAC), vol. 79, no. 9, Sept. 2024, pp. 2364–68. EBSCOhost, https://doi.org/10.1093/jac/dkae237.
APA
Gras, E., Aiello, T. F., Chumbita, M., Gallardo-Pizarro, A., Monzó-Gallo, P., Teijón-Lumbreras, C., Suárez-Lledó, M., Magnano, L., Tuset, M., Marcos, M. Á., Soriano, A., & Garcia-Vidal, C. (2024). Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes. Journal of Antimicrobial Chemotherapy (JAC), 79(9), 2364–2368. https://doi.org/10.1093/jac/dkae237
Chicago
Gras, Emmanuelle, Tommaso Francesco Aiello, Mariana Chumbita, Antonio Gallardo-Pizarro, Patricia Monzó-Gallo, Christian Teijón-Lumbreras, Maria Suárez-Lledó, et al. 2024. “Extended Remdesivir Administration in Haematological Patients with Malignancies and COVID-19 during the Omicron Era: Safety and Outcomes.” Journal of Antimicrobial Chemotherapy (JAC) 79 (9): 2364–68. doi:10.1093/jac/dkae237.